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Abstract
The aim of the study was to increase the efficiency of restorative treatment of patients with Acute Coronary
Syndrome (Miocardial Infarction) by incorporating the protocol therapy for the course of parenteral use of
L-arginine and L-carnitine (Tivorel).
It has been determined that patients with ACS (MI) after percutaneous coronary intervention often develop
reperfusion syndrome with manifestations of left ventricular insufficiency and rhythm disturbances. Substantial
clinical and functional improvement was noted under the influence of standard medical treatment in patients
of control group. At the same time postinfarction remodeling with systolic and diastolic function of the heart,
with the development of heart failure syndrome and endothelial dysfunction of blood vessels, and also remained
resistant to extrasystole therapy, progressed.
Patients in the experimental group under the influence of complex medical treatment with the inclusion of
L-arginine and L-carnitine marked a significant decrease in the frequency of violations of rhythm and conduction
for the second day of observation, as well as a decrease in the manifestations of post-infarction remodeling of LV,
which ultimately manifested a significant improvement in myocardial contractility (EF increased by 13%) and
decreased diastolic dysfunction. Improvement of the inotropic function of the heart and a significant reduction in
the frequency and severity of reperfusion arrhythmias was achieved precisely due to cardiometabolic effects of
L-carnitine. In addition, in patients undergoing additional treatment with L-arginine and L-carnitine after 10 days
of treatment, the activity of ET-1 was significantly lowered and the concentration of nitrogen oxide metabolites in
the blood plasma increased and reach the level of healthy subjects (p>0.05). So, they recovered the endothelial
function of the vessels.
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Problem statement and analysis of
the latest research
Despite of certain achievements of modern cardi-
ology, mortality from diseases of the circulatory
system in our country, it is in first rank in the struc-
ture of the mortality causes (67%) and makes 140.6
per 100 thousand able-bodied population. More-
over, there is an increase in the incidence of my-
ocardial infarction among persons of working age
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(48.9 per 100 thousand), and coronary heart disease
(CHD) continues to rank first place in the struc-
ture of the causes of primary disability (22.8%) [4].
The above facts determine the priority development
and improvement of treatment methods for patients
with acute coronar syndrome (myocardial infarc-
tion) [2, 7, 8].
The immediate cause of the development of
ACS (MI) is the rupture of the atheromatous plaque
and the formation of a blood clot in the coronary
artery, which causes progressive stenosis. At the
same time, the key role of such pathogenetic factors
as dislipidemia, systemic low intensity inflamma-
tion, peroxid stress and endothelial function dis-
orders, which underlie the violation of energetic
metabolism and ischemic damage of cardiomyocytes,
are discussed in the recent time. The indicated
pathogenetic mechanism of development of ACS
(MI) provides the possibility of medication influ-
ence on these pathological processes of metabolic
and cytoprotective therapy.
The most promising and physiological metabolic
preparations were L-carnitine and L-arginine. Many
studies have shown that L-arginine has antihypoxic,
membrane-stabilizing, antioxidant and detoxifica-
tion activity, manifests itself as an active regulator
of intermediate metabolism and energy supply pro-
cesses [6, 14], but its main physiological role is the
regulation of the functional state of vessels and the
provision of appropriate the level of microcircula-
tion of organs and tissues of the body [11, 13]. L-
carnitine plays an important role in energy exchange
in the myocardium by transferring free fatty acids
from the cytosol into the mitochondria, providing
the bioavailability of the high-energy substrate for
the oxidative metabolism in the cardiomyocyte [9,
16], that makes positive effects on the metabolism
and function of the left ventricle [10, 12, 17, 18].
The above facts became the basis for the study
of clinical effectiveness and the possibility of cor-
rection of metabolic disorders in patients with ACS
(MI).
The objective of the study: to increase the
efficiency of rehabilitation of patients with ACS
(MI) by incorporating into the protocol schedule
of the course of parenteral use of L-arginine and
L-carnitine (Tivorel).
1. Materials and Methods
A total of 45 patients with acute coronary syndrome
with ST segment elevation were investigated, who
had undergone urgent balloon angioplasty and stent-
ing of a heart attack-dependent coronary artery, and
were treated at the cardiology department of the
Ternopil University Hospital in 2018. The study
selected patients aged 43 to 75 years, on average
(59.57 ± 8.07) years. Among the studied contin-
gent, men dominated (82.2%). The diagnosis was
verified according to ESC recommendations [15]
in the presence of a typical angina attack, the dy-
namics of specific changes in the electrocardiogram
curve (ST segment rejection) and signs of necro-
resorptive syndrome.
The experimental group consisted of 30 patients,
who received standard protocol treatment of ACS
(MI) and additionally were prescribed 4.2 g L-arginine
and 2.0 g L-carnitine (Tivorel) in the 100 ml solu-
tion for infusion once daily for 5 days intravenously.
The control group included 15 patients with ACS
(MI) who also had urgent balloon angioplasty and
stenting of the heart attack-dependent coronary artery,
but this group received only standard protocol treat-
ment.
In addition to general clinical, instrumental and
laboratory methods (general blood test, MB Cre-
atinephosphokinase fraction (CFC-MB), Troponin
T, oxygen saturation of arterial blood (SpO2), ECG
in 12 standard leads, etc.), performed an echocardio-
graphy in the B-mode with the Aloka SSD - 2000 ”
(USA) with the definition of linear and volume indi-
cators of the left ventricle, as well as the global (by
the ejection fraction (EF) and local contractile activ-
ity of the myocardium by the Simpson method.The
diastolic function of the left ventricle was evaluated
with the time of isovluminous relaxation left ven-
tricle (IVRT), sometimes delayed rate of early left
ventricular filling (DT), maximal rate of its early
filling (E), and maximum left ventricular filling ve-
locity in the period of the atrial systole (A) [1].
The functional state of the vascular endothelium
was determined by the concentration of endothelin-
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1 (ET-1) in the blood plasma and the content of
stable NO metabolites [5]. The determination of
endothelin-1 (ET-1) in serum was carried out using
the Amersham Pharmacia Biotech Immuno-enzyme
Kit and the affinity chromatography columns of the
same firm as instructed. The method for determin-
ing the ultimate stable metabolites of NO in the
blood is based on the restoration of nitrates (NOs)
to nitrites (NO2) with the determination of the latter
by reaction with the Gris reagent. Calculation of
the amount of nitrites is carried out according to the
calibration schedule. There were received 3 results:
the content of nitrate ions (Kmol/L, the content of
nitrite ions (Kmol/L) and the total content of nitrite
and nitrate ions (Kmol/L).
The statistical processing of the obtained results
was performed using the statistical program pack-
age ”Statistica 10.0” and the ”Microsoft Exel-2013”
program. Non-parametric statistical methods were
used to assess the data - Mann-Whitney U-test for
comparison of indicators in two groups (p<0.05).
2. Results and Discussion
Among the examined, ACS (MI) in men, was met
in 4.6 times more often than in women, which is
comparable to the literature data. In most cases,
ACS has developed on the background of arterial
hypertension in 27 (60.0%) persons. Dislipidemia
or hypercholesterolemia (total cholesterol ≥ 4.5
mmol/L, Low density lipoprotein (LDL) choles-
terol ≥ 1.8 mmol/L, Th ≥ 2.0 mmol/L) occurred
in 38 (84.4%) patients. In 31 (68.4%) patients
combination of these two risk factors for IHD was
traced. Among other unfavorable factors, the body
weight was noted in 14 (31.1%) patients, type 2
diabetes mellitus (12.7%), and smoking in 28 pa-
tients (62.2%). Among women dominant persons
of the elder age (7 patients) and all 9 women were
in menopause.
The clinical picture of ACS (MI) in most of
the examined patients was manifested by classical
angina pectoris, characteristic changes in the elec-
trocardiographic curve and necro-resorptive syn-
drome. Some patients (11.1%) were diagnosed with
an atypical clinical onset of myocardial infarction.
Violations of heart rhythm and conduction were
diagnosed in 93 (65%) of examined patients, most
often ventricular or supraventricular extrasystoles
(in 78.5%), paroxysms of atrial fibrillation (in 11.8%),
ventricular tachycardia (in 5.4%), ventricular tachy-
cardia blockade of different degree and localization
(in 45.1%).
All patients were tested for morphological and
functional cardiac examination and contrast coro-
nary angiography with subsequent angioplasty and
stenting of the infarct-dependent coronary artery
(on average, after 6.28 ± 1.43 hours after the onset
of an angina attack). According to the results of
the urgent coronary angiography (UCA), the final
diagnosis was established for each patient. It can be
stated that the number and anatomical severity of
coronary artery disease did not differ significantly
between patients of these groups (Fig. 1).
Analyzing the structure and frequency of devel-
opment of complications in the examined groups
of patients, it was found that development of acute
aneurysm of the anterior wall of the left ventricle
(33.3% vs. 0.0%, p = 0.017) and thromboendo-
carditis in the apex of the left ventricle (26.7% ver-
sus 0.0 %, p = 0.037) were significantly more fre-
quent in patients undergoing protocol medication
and cardio-rehabilitation treatment. At the same
time, the patients in the experimental group, who
were additionally prescribed a course of therapy
with L-arginine and L-carnitine in the complex med-
ical treatment, did not show any complications at all.
Moreover, in the examined patients of both groups,
which timely (within 2 to 12 hours after the onset of
an anginal attack) had urgent angioplasty and stent-
ing of the heart attack-dependent coronary artery,
such complications as early post-infarction angina,
cardiogenic shock, pulmonary edema, mechanical
(rupture free wall of the left ventricle, interventric-
ular septum, separation of papillary muscles) have
not been recorded at all. At the same time, it should
be noted that in patients with ACS, in the postoper-
ative period (after percutaneous coronary interven-
tion) reperfusion syndrome with different duration
and severity of left ventricular insufficiency and
violations of rhythm and conduction was most of-
ten developed (Fig. 2). As can be seen from the
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(a) (b)
Figure 1. The structure of the distribution of the frequency of coronary artery damage in patients with
ACS (MI) of experimental (a) and control (b) groups.
data presented, in the initial state immediately after
the performed PK in patients with ACS (MI) both
groups recorded the same frequency and types of
violations of rhythm and conductivity (p>0.05).
Under the influence of standard medical and
restorative treatment, a significant decrease in the
frequency of rhythm and conduction disorders in
patients in the control group was observed for the
second day of observation. Resistance to such treat-
ment remained supraventricular and ventricular ex-
trasystoles and blockades of the legs of the Gissa
bundle. Moreover, these arrhythmias remained at
the end of the second week of treatment, which jus-
tified the use of additional antiarrhythmic therapy.
Patients with ACS (MI) of the experimental
group under the influence of complex medical treat-
ment with the inclusion of L-arginine and L-carnitine
also noted a significant decrease in the frequency
of violations of rhythm and conduction already
the second day of observation, but patients in this
group had significantly higher sinus tachycardia and
supraventricular extrasystoles. This result can be
explained by an additional decrease in systolic and
diastolic blood pressure due to the improvement of
microcirculation under the influence of L-arginine.
However, it should be noted that at the end of the
course of the proposed comprehensive treatment (8-
10 days), the frequency of violations of rhythm and
conduction in patients in the experimental group
was significantly lower compared with the compari-
son group (p<0.05).
The results of the Echo-Cardiographic study
(Table 1) show that in the initial state of patients
with ACS (MI) of the experimental and control
groups they do not differ statistically, but differ sig-
nificantly from those of healthy people (referent
values). At the same time, it should be noted that
systolic and diastolic LV dysfunction was diagnosed
in patients with ACS (MI), as evidenced by an in-
crease in the incidence of LDV lv, LSV lv, A, IVRT,
DT and decreased FE, E, E/A. The short-term left
ventricular function due to the development of ACS
(MI) decreased by an average of 22%.
Under the influence of standard therapy for up
to 10 days in patients with ACS (MI), indices of
LDV lv, IVRT, DT, A significantly increased, re-
spectively, and such indices of intracardiac hemody-
namics as E, E/A, FE were decreased. Thus, on the
10th day of the MI in patients with control group,
in the background of medical and restorative treat-
ment according to the standard scheme, there was a
remodeling of the heart with a gradual increase in
the volume of its cells and decreased contractility.
At the same time, patients developed diastolic dys-
function mainly due to the relaxation type. After a
one-month course of standard treatment in patients
with this group, there was a continuation of post-
infarction remodeling of the lungs, which was mani-
fested by a significant increase in LDS lv, IVRT, DT
and a decrease in E, E/A. FE somewhat increased
to 28 days of ongoing therapy (by 1.5-4.3%) com-
pared to an index of 1-10 days of standard treatment
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Figure 2. Frequency of development of violations of rhythm and conduction in patients with ACS (MI)
in experimental (A) and control (B) groups.
Table 1. Dynamics of hemodynamic parameters under the influence of complex therapy with the
inclusion of L-arginine and L-carnitine in patients with ACS (MI) (M±m).
Indication and their
referent values
1 st day 10 th day 28 th day p1 p2 p3
LDV lv, ml 1 151.5±1.2 146.3±1.4 144.4±1.4 <0.05 <0.05 <0.05
(156.4±1.4) 2 152.1±1.4 158.8±1.6 159.2±1.6 <0.05 <0.05 <0.05
LSV lv, ml 1 88.6±2.7 86.5±3.2 81.3±2.8 >0.05 >0.05 <0.05
(81.3±3.8) 2 89.3±2.3 89.4±2.5 93.9±2.3 >0.05 >0.05 >0.05
FE, % 1 46.9±0.4 51.2±0.2 53.8±0.23 <0.05 >0.05 <0.05
(59.8±0.3) 2 47.9 ±0.4 46.5±0.3 48.6±0.6 >0.05 >0.05 >0.05
IVRT,ms 1 82.6±1.3 76.3±1.3 68.1±2.1 <0.05 <0.05 <0.05
(88.5±2.1) 2 83.7±2.1 78.4±1.5 74.3±2.1 >0.05 >0.05 <0.05
DT, ms 1 169.9±5.3 185.4±5.2 234.4±4.8 <0.05 <0.05 <0.05
(196.4±4.7) 2 179.5±4.4 186.6±4. 6 194.6±4.5 >0.05 >0.05 >0.05
E, sm/s 1 61.5±1.8 63.2±1.8 65.61±1.6 >0.05 >0.05 <0.05
(45.67±1.7) 2 62.2±1.3 53.2±1.3 48.7±1.4 <0.05 >0.05 <0.05
A, sm/s 1 44.3±1.3 37.2±1.2 32.8±1.1 <0.05 <0.05 <0.05
(36.8±1.1) 2 42.7±1.1 48.5±1.2 54.8±1.1 <0.05 <0.05 <0.05
E/A 1 1.36±0.04 1.43±0.04 1.03±0.04 >0.05 <0.05 <0.05
(1.23±0.04) 2 1.44±0.05 1.35±0.06 1.19±0.05 >0.05 >0.05 <0.05
Notes:
1. 1,2 - accordingly indicators in patients with MI (n=30) and control group (n=15);
2. p1, p2, p3 – the rates are significantly different in patients with MI in the 1st and 10th day of the treatment, on
the 10th and 28th day and in patients on the 1st and 28th day;
3. The underlying values are significantly different from those in the control group (p<0.05).
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(p<0.05). However, this indicator after the comple-
tion of treatment was significantly lower than in
healthy subjects. The obtained data indicate insuffi-
cient hemodynamic efficacy of standard therapy in
this group of patients.
In patients with ACS (MI) of the experimental
group, who received treatment with L-arginine and
L-carnitine before the standard therapy, a significant
increase in DT and FS and a decrease in LDV lv
and E/A, changes in the rest hemodynamic indices
were insignificant compared to the baseline data,
but there was a tendency towards a decrease in post-
arterial cardiac remodeling. At the same time, the
development of diastolic dysfunction according to
the relaxation type was noted. Thus, on the 28th day
of the applied therapy, the IVRT and FE values in-
creased significantly and E, A, E/A decreased com-
pared with the original value. Thus, the addition to
standard medical and restorative treatment in these
patients L-arginine and L-carnitine contributed to
the reduction of the size of the left chambers of the
heart, manifestations of post-infarction remodeling
of the lungs, which eventually showed a significant
increase in FE (an average of 13%), myocardial
contractility and diminished diastolic dysfunction.
A promising task was also to clarify the pecu-
liarities of changes in the parameters of endothelial
function of the vessels in patients with acute my-
ocardial infarction (MI). In the course of the study,
it was found that in the initial state, the parameters
of the functional state of the endothelium in patients
with ACS (MI) of the two groups under study did
not differ significantly among themselves, but were
significantly affected in comparison with the refer-
ence ones. Thus, when entering the treatment, the
level of endothelin-1 in blood plasma in patients
with ACS (MI) was 2.1 times higher than the ref-
erence norm (respectively, 0.96 ± 0.04 and 0.46
± 0.03 ng/ml) and its activity did not significantly
change immediately after the urgent angioplasty of
the coronary vessel and its stenting. At the same
time, the patients in the control group undergoing
protocol medication and rehabilitation, the level of
endothelinum decreased significantly, but at the end
of the inpatient stage of treatment did not reach the
level of healthy subjects (0.66 ± 0.06; p>0.05).
In contrast, patients of the experimental group
who additionally included a course of therapy with
L-arginine and L-carnitine for the next 10 days of
inpatient treatment, the activity of ET-1 decreased
by 33.3% (p<0.05), and after one month of treat-
ment, its activity in blood plasma was significantly
lower by 43% and reached the level of healthy sub-
jects (0.52 ± 0.05 ng/ml; p>0.05). That is, the use
of integrated drug therapy with the inclusion of L-
arginine and L-carnitine against the background of
an individualized cardio-rehabilitation program in
patients with SCS contributed to a rapid decrease
(within 10 days) and complete restoration (within
28 days) of endothelin-1 activity in plasma these
patients.
Simultaneously with changes in the activity of
endothelin-1 in patients with corticosteroids (MI)
in the period of exacerbation of the disease there
was a sharp decrease in the level of metabolites
of nitric oxide (NOε = 17.75 ± 0.42 mkmol/l at
normal – 36.92 ± 0.37 mkmol/l), that could indi-
cate a marked microcirculation disorder in these
patients. So the concentration of nitrates and ni-
trites in the initial state in patients of both groups
decreased by almost 2.0 times, and their total con-
tent in blood plasma dropped by 45.0%. It should be
noted that the generally used protocol treatment did
not ensure the complete restoration of the endothe-
lial function of the vessels in this group of patients
with ACS (MI), the total concentration of metabo-
lites of nitric oxide in plasma was 19% lower than
the reference index (p<0.05). At the same time,
the use of integrated drug therapy with the inclu-
sion of L-arginine and L-carnitine in patients in
the experimental group significantly affected the
concentration of nitrites and nitrates in the blood
plasma, their level significantly increased already in
10 days of treatment and at the end of the inpatient
stage of the complex drug and restorative cardio-
rehabilitation treatment has reached the reference
norm.
Thus, the obtained results of the comprehensive
study of the clinical and functional state of patients
with ACS (MI) suggest that in most cases, ACS (MI)
has developed on the background of a combination
of such risk factors as arterial hypertension, dis- or
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hypercholesterolemia, excess body weight, diabetes
mellitus Type 2 and smoking (in more than 60% of
all subjects). The clinical picture of ACS (MI) in
the most of examined patients was manifested by
classical angina pectoris, characteristic changes in
the electrocardiographic curve and necro-resorptive
syndrome, and atypical clinical onset of myocardial
infarction was diagnosed in 11.1% of patients. It
should be noted that in patients with ACS, in the
postoperative period (after percutaneous coronary
intervention), reperfusion syndrome with varying
durability and severity of left ventricular insuffi-
ciency and rhythm and conduction disorders were
most often developed. Under the influence of stan-
dard medical and restorative treatment in patients
in the control group, a significant decrease in the
frequency of rhythm and conduction disturbances
in the control group was observed for the second
day of observation, but supraventricular and ven-
tricular extrasystoles and obstruction of the legs of
the GIS beam remained resistant to such treatment,
which justified the use of additional antiarrhythmic
therapy At the same time, patients with ACS (MI)
of the experimental group under the influence of
complex medical treatment with the inclusion of
L-arginine and L-carnitine on the background of
an individualized cardio-rehabilitation program for
the second day of observation marked a significant
decrease in the frequency of violations of rhythm
and conduction, but remained significantly higher
the frequency of sinus tachycardia and supraventric-
ular extrasystoles, which could be explained by the
compensatory response to an additional decrease
in systolic and diastolic blood pressure under the
influence of the proposed this treatment.
Diagnosis in the initial state of patients with
acute myocardial infarction (MI) of marked viola-
tions of the morpho-functional parameters of the
heart, post-infarction remodeling with violation of
systolic and diastolic function of the heart, with
the development of the syndrome of heart failure
and endothelial dysfunction of the vessels that were
stored immediately after an urgent percutaneous
intervention, became the basis for inclusion in the
protocol of the therapy program of parenteral use of
L-arginine and L-carnitine. It was found that in the
initial state of patients with acute myocardial infarc-
tion (MI) there was a remodeling of the heart with
a gradual increase in the volume of its chambers
and decreased contractile ability and the simultane-
ous development of diastolic dysfunction, mainly
in the relaxation type, and the course of standard
treatment did not stop post-infarction remodeling of
LV, although the FE was somewhat increased, not
reaching the level of healthy persons. That is, the
findings suggest insufficient hemodynamic efficacy
of standard therapy in this group of patients.
Patients with ACS (MI) of the experimental
group who received standard therapy with treatment
with L-arginine and L-carnitine on the background
of an individualized cardio-rehabilitation program,
with a re-examination (10 days), a significant in-
crease in FE, DT, and a decrease in LDV lv, the
coefficient E/A, and this tendency to reduce postin-
farction remodeling of the heart, which eventually
manifested a significant increase in FE, myocar-
dial contractility and decreased diastolic dysfunc-
tion. The obtained positive effect of the proposed
treatment on the inotropic function of the heart and
a significant decrease in the frequency and sever-
ity of reperfusion arrhythmias, in our opinion, was
achieved precisely due to the cardiometabolic ef-
fect of L-carnitine, which, according to many re-
searchers, plays an important role in the energy ex-
change in the myocardium due to the transfer of free
fatty acids from the cytosol within the mitochondria
and thus provides the bioavailability of the high-
energy substrate for the oxidative metabolism in the
cardiomyocyte [10, 12]. In addition, by facilitating
the oxidation of long chain fatty acids and modu-
lating the ratio of KoA to KOA-SH, the compound
is involved in the binding of acyl residues in per-
oxisomes and mitochondria and positively affects
the exchange of amino acids by assimilating the
array of free radical compounds, which ensures the
stabilization of organelles and cellular membranes
and It prevents the accumulation in the cytoplasm
of cardiomyocytes of fatty acid esters, which can
lead to fatal ventricular arrhythmias [16, 17, 18].
In the course of the study, it was also found
that in the initial state, the indexes of the functional
state of the endothelium in patients with ACS (MI)
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of both groups under study were significantly af-
fected in comparison with the reference (p<0.05)
and were manifested by marked microcirculation
disorders due to a significant increase in the activity
of endothelin- 1 and lower levels of nitric oxide pro-
duction. At the same time, patients in the control
group undergoing protocol medication and rehabili-
tation significantly decreased the endothelin level,
while the concentration of nitric oxide metabolites
in the blood plasma increased, but at the end of
the inpatient stage, they did not reach the level of
healthy subjects (p<0.05).
In contrast, patients in the experimental group
who additionally included a course of therapy with
L-arginine and L-carnitine on the background of an
individually-adapted cardio-rehabilitation program
after 10 days of treatment, has the significantly de-
creased activity of the ET-1 and the concentration of
nitrogen oxide metabolites in blood plasma, reach-
ing the level of healthy persons (p>0.05). That is,
such complex treatment in patients with ACS (MI)
contributed to the rapid and complete restoration
of the studied parameters of endothelial function
of the blood vessels. The result of the treatment
can be explained by the use of L-arginine as the
main substrate for the synthesis of nitric oxide. In
many studies, it has been demonstrated that the use
of L-arginine after stenting reduced the number of
restenoses [3, 6, 14] due to its antihypoxic, antioxi-
dant and membrane-stabilizing activity, but its main
physiological role is the regulation of the functional
state of vessels and the provision of an appropriate
level of microcirculation of organs and tissues of
the body [11, 13, 16].
In general, due to the complex application of
combined drug therapy with the inclusion of L-
arginine and L-carnitine (Tivorel) on the background
of an individualized cardio-rehabilitation program,
a significant improvement in the parameters of cen-
tral cardioghemodynamics and restoration of en-
dothelial function of the vessels was achieved, that
was accompanied by a significant decrease in the in-
cidence and severity of such complications of ACS
as reperfusion arrhythmias and acute cardiac (left
ventricular) insufficiency.
3. Conclusions
1. In patients with acute myocardial infarction
(MI) in the initial state there are marked viola-
tions of morpho-functional parameters of the
heart, the development of its post-infarction
remodeling with violation of systolic and di-
astolic function of the heart and development
of the syndrome of heart failure and endothe-
lial dysfunction of blood vessels.
2. Morpho-functional disorders of the heart pa-
rameters led to the development of compli-
cated flow of ACS (MI), in the first day after
percutaneous coronary intervention on the
background of standard medical and restora-
tive therapy, the reperfusion syndrome with
manifestations of acute left ventricular insuf-
ficiency and rhythm and conduction disorders
were most often diagnosed.
3. The use of integrated drug therapy with the
inclusion of L-arginine and L-carnitine (Ti-
vorel) on the background of an individualized
cardio-rehabilitation program resulted in a
significant improvement of the parameters
of central cardiohemodynamics and restora-
tion of endothelial function of the vessels,
accompanied by a significant decrease in the
incidence and severity of such complications
of ACS (MI) as reperfusion arrhythmias and
acute left ventricular failure.
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